Key facts
- Kriya’s last known valuation is $870.0M (Jul 2023).
- It has raised $940.5M; the latest was Later Stage VC ($320.8M) in Aug 2025.
- Notable investors include Alumni Ventures, Foresite Capital, Peter Thiel, Sabrina Hahn, Premji Invest — 25 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Kriya
- ·The full record, as it builds
Funding rounds
No funding rounds for Kriya are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kriya
Operator of a gene therapeutics company intended to design and develop gene therapies for diseases with underlying biology. The company utilizes a vector design platform to enhance its capabilities in de novo construct design, targeted sequence modification and data analysis, enabling physicians to minimize immunogenicity and improve tissue specificity.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2019
- Employees
- 189
- Website
- kriyatherapeutics.com/
- Ownership
- Privately Held (backing)
Kriya doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kriya shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kriya in its N-PORT filings yet. We sweep new filings monthly.